For decades, Alzheimer’s disease has been treated as a problem that begins and ends inside the brain. A new study suggests part of the story starts somewhere much more accessible: the lymph nodes.

Researchers at Washington University School of Medicine in St. Louis report that, in mice, the immune cells driving Alzheimer’s-like neurodegeneration receive their marching orders outside the brain. When the team interrupted that process, brain damage dropped dramatically. The work was published on September 3, 2026 in Nature Neuroscience.

An immune puzzle inside the Alzheimer’s brain

T cells normally patrol the body, hunting down infected or damaged cells. In the brains of people with Alzheimer’s disease and related disorders, they show up in much higher numbers than in healthy brains, and they seem to make the damage worse. What nobody could explain was where these cells came from or what pulled them into the brain in the first place.

The lab of neurologist David Holtzman had already shown that removing T cells protected mice from the neurodegeneration caused by toxic tau protein, the twisted clumps that build up in Alzheimer’s disease and in a group of conditions called primary tauopathies. The new question was: who is telling those T cells what to attack?

The trainers: dendritic cells

Many T cells need a partner, called a dendritic cell, to show them which molecular targets to go after. The specific type involved here, known as cDC1, is scarce in the brain, and the few that are present don’t appear to interact with the T cells that arrive once tau tangles form. That pointed the researchers toward the rest of the body.

They tested this in mice that normally develop tau tangles and neurodegeneration. Removing dendritic cells from the lymph nodes and other locations brought the surge of CD8 T cells in the brain back down, and much of the brain damage disappeared with it. Strikingly, the amount of tau in the brain didn’t change. The tangles were still there; the immune attack on the brain was what had been reduced. The mice also kept their cognitive abilities, hinting that calming this immune pathway could slow the mental decline seen in Alzheimer’s.

What sets the process off?

The exact trigger isn’t known yet. The leading idea is that tau-damaged brain cells release material that drains toward the lymph nodes in the neck. There, dendritic cells flag it as a threat and train T cells to hunt it down, sending them to the brain, where they do more harm than good.

Why this matters for treatment

One of the biggest hurdles in treating brain diseases is getting a drug past the blood-brain barrier. A driver that operates outside the brain could sidestep that problem entirely. T cells and dendritic cells are already well studied, and many ways of manipulating them are approved for other diseases, though few have been tried in neurodegeneration.

Important caveats apply. This is mouse research, and in these experiments the dendritic cells were blocked from birth, long before any disease would appear. The team is now testing whether intervening in midlife, closer to when tau tangles begin to form in people, works as well, and they are trying to identify the signal that guides T cells to the brain so it can be blocked.

Still, the findings add to a growing shift in the field: the immune system, once considered a bystander in protein-driven brain diseases, is increasingly looking like an active player and a possible target.

Sources

News release: WashU Medicine

Original paper: Hu H, et al. Priming of CD8+ T cells by peripheral dendritic cells exacerbates tau-mediated neurodegeneration. Nature Neuroscience, September 3, 2026. https://www.nature.com/articles/s41593-026-02427-5